Innovation is the cornerstone of AbbVie’s business as a global biopharmaceutical company. Their focus is on developing medicines that can provide strong clinical performance, measurable patient benefit and economic value, particularly in areas where there is significant need, such as hepatitis C, neuroscience, immunology, oncology, chronic kidney disease and women’s health.
AbbVie combines advanced science, global capabilities and passion to provide innovative therapies that help people manage some of the most serious health conditions.
member
The Government of Canada is investing $2 billion to support diagnostic testing and to purchase ventilators and protective personal equipment, including for bulk purchases with provinces and territories.
Sign up for one of BAM's newsletter to learn more about bioscience, happenings in Manitoba's bioeconomy, industry conferences, and BAM training events.